Biotech J&J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early trial

Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.

The Chinese CAR-T player plans to list its stock on the Nasdaq under the ticker "LEGN" to fund the advance of a pipeline spearheaded by Johnson & Johnson-partnered anti-BCMA therapy JNJ-4528, which is in early- to midstage trials.